Cereno Scientific’s board of directors and management enter lock-up agreements
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that its board of directors and management have signed lock-up agreements for their shares and/or other securities in the company until publication of the report from the data quality control of CardioMEMS measurements.The members of the board of the directors and management have entered into agreement not to sell their shares and/or other securities in the company in any way, also known as lock-up agreements, during the period from and